1. Home
  2. CANF vs HLN Comparison

CANF vs HLN Comparison

Compare CANF & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.22

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Haleon plc (Each representing two)

HLN

Haleon plc (Each representing two)

HOLD

Current Price

$10.06

Market Cap

43.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
HLN
Founded
1994
2022
Country
Israel
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
43.7B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CANF
HLN
Price
$3.22
$10.06
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$9,750.00
N/A
AVG Volume (30 Days)
609.7K
8.3M
Earning Date
03-27-2026
02-26-2026
Dividend Yield
N/A
1.77%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$461.72
$7.04
Revenue Next Year
$290,391.28
$4.58
P/E Ratio
N/A
$49.05
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$8.71
52 Week High
$10.40
$11.42

Technical Indicators

Market Signals
Indicator
CANF
HLN
Relative Strength Index (RSI) 35.75 40.69
Support Level $0.60 $9.98
Resistance Level $4.74 $10.31
Average True Range (ATR) 0.64 0.15
MACD -0.17 -0.03
Stochastic Oscillator 0.90 14.30

Price Performance

Historical Comparison
CANF
HLN

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About HLN Haleon plc (Each representing two)

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Share on Social Networks: